Chugai Pharmaceutical Co Ltd

Common Name
Chugai Pharmaceutical
Country
Japan
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
5,026
Ticker
4519
Exchange
TOKYO STOCK EXCHANGE
Description
Chugai Pharmaceutical Co., Ltd. is a prominent pharmaceutical company involved in research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Its primary aim is to ...

Chugai Pharmaceutical's Financial Statements Preview

Below are the financial statements of Chugai Pharmaceutical, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of JPY
2024
2023
Revenue
1,170,611a
1,111,367a
Sales
997,901a
974,493a
Other revenue
172,710a
136,874a
Cost of sales
-339,409a
-413,306a
Gross profit
831,201a
698,061a
Research and development
-181,440a
-174,868a
Selling, general and administration
-110,098a
-112,580a
Other operating income (expense)
2,339a
28,561a
Operating profit
542,002a
439,174a
Financing costs
-5a
-27a
Other financial income (expense)
1,027a
4,674a
Profit before taxes
543,034a
443,821a
Income taxes
-155,717a
-118,349a
Net income
387,317a
325,472a
Attributable to
Chugai shareholders
387,317a
325,472a
Download Data

Verified Sources Behind Chugai Pharmaceutical’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Chugai Pharmaceutical’s data sources below and access millions more through our Disclosure Search.

a. Chugai Pharmaceutical's Financial Report 2024
a. Chugai Pharmaceutical's Financial Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?